Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

M Glass, 1997, Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain, Neuroscience, 77, 299, 10.1016/S0306-4522(96)00428-9

ES Onaivi, 2011, Commentary: functional neuronal CB2 cannabinoid receptors in the CNS, Current Neuropharmacology, 9, 205, 10.2174/157015911795017416

BK Atwood, 2010, CB2: a cannabinoid receptor with an identity crisis, British Journal of Pharmacology, 160, 467, 10.1111/j.1476-5381.2010.00729.x

L De Petrocellis, 2010, Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels, Journal of Neuroimmune Pharmacology, 5, 103, 10.1007/s11481-009-9177-z

V Di Marzo, 1998, ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance, Biochimica et Biophysica Acta - Lipids and Lipid Metabolism, 1392, 153, 10.1016/S0005-2760(98)00042-3

V Di Marzo, 2011, Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes, Handbook of Experimental Pharmacology, 75, 10.1007/978-3-642-17214-4_4

FJ Bermudez-Silva, 2010, The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning, Pharmacology Biochemistry and Behavior, 95, 375, 10.1016/j.pbb.2010.03.012

EB Russo, 2004, Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions, Neuro Endocrinol Lett, 25, 31

E Fride, 2004, The endocannabinoid-CB receptor system: Importance for development and in pediatric disease, Neuroendocrinology Letters, 25, 24

MN Hill, 2005, Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression, Behav Pharmacol, 16, 333, 10.1097/00008877-200509000-00006

A Giuffrida, 2004, Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms, Neuropsychopharmacology, 29, 2108, 10.1038/sj.npp.1300558

P Sarchielli, 2007, Endocannabinoids in chronic migraine: CSF findings suggest a system failure, Neuropsychopharmacology, 32, 1384, 10.1038/sj.npp.1301246

M Di Filippo, 2008, Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis, Journal of Neurology Neurosurgery and Psychiatry, 79, 1224, 10.1136/jnnp.2007.139071

KL Allen, 2009, Cannabinoid (CB1), GABA_A and GABA_B receptor subunit changes in the globus pallidus in Huntington's disease, Journal of Chemical Neuroanatomy, 37, 266, 10.1016/j.jchemneu.2009.02.001

K Van Laere, 2010, Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo, Journal of Nuclear Medicine, 51, 1413, 10.2967/jnumed.110.077156

V Pisani, 2010, Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients, Movement Disorders, 25, 920, 10.1002/mds.23014

BS Wong, 2012, Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea, Neurogastroenterology and Motility, 24

N Gerard, 2011, Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa, Biological Psychiatry, 70, 777, 10.1016/j.biopsych.2011.05.010

A Chouker, 2010, Motion sickness, stress and the endocannabinoid system, PLoS ONE, 5, 10.1371/journal.pone.0010752

P Sandercock, 2002, Systematic reviews of animal experiments, Lancet, 360, 586, 10.1016/S0140-6736(02)09812-4

MR Macleod, 2004, Pooling of animal experimental data reveals influence of study design and publication bias, Stroke, 35, 1203, 10.1161/01.STR.0000125719.25853.20

JM McPartland, 2007, Meta-analysis of cannabinoid ligand binding affinity and cannabinoid receptor distribution: interspecies differences, British Journal of Pharmacology, 152, 583, 10.1038/sj.bjp.0707399

HB van der Worp, 2011, Preclinical studies of human disease: time to take methodological quality seriously, Journal of Molecular and Cellular Cardiology, 51, 449, 10.1016/j.yjmcc.2011.04.008

A Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, e1000100, 10.1371/journal.pmed.1000100

JM McPartland, 2000, Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study, J Am Osteopath Assoc, 100, 89

JR Hornberg, 2013, Measuring behaviour in rodents: towards translational neuropsychiatric research, Behavioural Brain Research, 236, 295, 10.1016/j.bbr.2012.09.005

CJ Fowler, 1999, Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen, Archives of Biochemistry and Biophysics, 362, 191, 10.1006/abbi.1998.1025

L Bertolacci, 2013, A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase, Journal of the American Chemical Society, 135, 22, 10.1021/ja308733u

KR Kozak, 2002, Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides, J Biol Chem, 277, 44877, 10.1074/jbc.M206788200

N Sang, 2006, PGE₂ glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons, Journal of Physiology-London, 572, 735, 10.1113/jphysiol.2006.105569

SSJ Hu, 2008, Prostaglandin E-2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NF kappa B activity, British Journal of Pharmacology, 153, 1538, 10.1038/bjp.2008.33

L Gatta, 2012, Discovery of prostamide F-2 alpha and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability, Plos One, 7, 10.1371/journal.pone.0031111

J Kim, 2004, Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus, Nature Neuroscience, 7, 697, 10.1038/nn1262

H Gühring, 2002, A role for endocannabinoids in indomethacin-induced spinal antinociception, European Journal of Pharmacology, 454, 153, 10.1016/S0014-2999(02)02485-8

M Ates, 2003, Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test, European Journal of Neuroscience, 17, 597, 10.1046/j.1460-9568.2003.02470.x

DK Ahn, 2007, Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception, Pain, 132, 23, 10.1016/j.pain.2007.01.015

J Guindon, 2009, The endocannabinoid system and pain, CNS & Neurological Disorders-Drug Targets, 8, 403, 10.2174/187152709789824660

O Sasso, 2012, Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions, Pharmacological Research, 65, 553, 10.1016/j.phrs.2012.02.012

K Green, 2001, Interaction between Delta-9-tetrahydrocannabinol and indomethacin, Ophthalmic Research, 33, 217, 10.1159/000055673

M Perez Reyes, 1991, Antagonism of marihuana effects by indomethacin in humans, Life Sciences, 48, 507, 10.1016/0024-3205(91)90465-N

RB Easley, 2000, Central nervous system manifestations of an ibuprofen overdose reversed by naloxone, Pediatr Emerg Care, 16, 39, 10.1097/00006565-200002000-00012

JM McPartland, 2008, Cannabimimetic effects modulated by cholinergic compounds, Addiction Biology, 13, 411, 10.1111/j.1369-1600.2008.00126.x

ED Högestätt, 2005, Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system, Journal of Biological Chemistry, 280, 31405, 10.1074/jbc.M501489200

M Dania, 2007, The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors, European Journal of Pharmacology, 573, 214, 10.1016/j.ejphar.2007.07.012

A Ottani, 2006, The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors, European Journal of Pharmacology, 531, 280, 10.1016/j.ejphar.2005.12.015

C Mallet, 2008, Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia, Pain, 139, 190, 10.1016/j.pain.2008.03.030

SN Umathe, 2009, Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 33, 1191, 10.1016/j.pnpbp.2009.06.020

DA Andersson, 2011, TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid D⁹-tetrahydrocannabiorcol, Nature Communications, 2, 551, 10.1038/ncomms1559

GG Gould, 2012, Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 38, 260, 10.1016/j.pnpbp.2012.04.011

S Wang, 2007, Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats, Pain, 131, 96, 10.1016/j.pain.2006.12.019

RW Wu, 2011, Cannabinoid receptor 1 regulates ERK and GSK-3 beta-dependent glucocorticoid inhibition of osteoblast differentiation in murine MC3T3-E1 cells, Bone, 49, 1255, 10.1016/j.bone.2011.08.022

JY Ko, 2012, Cannabinoid receptor 1 mediates glucocorticoid-induced bone loss in rats by perturbing bone mineral acquisition and marrow adipogenesis, Arthritis and Rheumatism, 64, 1204, 10.1002/art.33457

S Di, 2003, Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism, Journal of Neuroscience, 23, 4850, 10.1523/JNEUROSCI.23-12-04850.2003

S Di, 2005, Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons, Endocrinology, 146, 4292, 10.1210/en.2005-0610

R Malcher-Lopes, 2006, Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release, Journal of Neuroscience, 26, 6643, 10.1523/JNEUROSCI.5126-05.2006

J Wang, 2012, Endocannabinoids mediate the glucocorticoid-induced inhibition of excitatory synaptic transmission to dorsal raphe serotonin neurons, Journal of Physiology-London, 590, 5795, 10.1113/jphysiol.2012.238659

MN Hill, 2010, Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo, Psychoneuroendocrinology, 35, 1333, 10.1016/j.psyneuen.2010.03.005

MN Hill, 2011, Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response, Journal of Neuroscience, 31, 10506, 10.1523/JNEUROSCI.0496-11.2011

MN Hill, 2008, Prolonged glucocorticoid treatment decreases cannabinoid CB₁ receptor density in the hippocampus, Hippocampus, 18, 221, 10.1002/hipo.20386

P Atsak, 2012, Glucocorticoids interact with the hippocampal endocannabinoid system in impairing retrieval of contextual fear memory, Proceedings of the National Academy of Sciences of the United States of America, 109, 3504, 10.1073/pnas.1200742109

NP Bowles, 2012, Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice, Neuroscience, 204, 83, 10.1016/j.neuroscience.2011.08.048

S Hong, 2009, Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat, Gut, 58, 202, 10.1136/gut.2008.157594

KV Allen, 2003, Regional differences in naloxone modulation of Δ⁹-THC induced Fos expression in rat brain, Neuropharmacology, 44, 264, 10.1016/S0028-3908(02)00364-7

DL Cichewicz, 2001, Changes in opioid and cannabinoid receptor protein following short-term combination treatment with Δ⁹- tetrahydrocannabinol and morphine, Journal of Pharmacology and Experimental Therapeutics, 297, 121

L Fattore, 2007, Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2, European Journal of Neuroscience, 25, 2191, 10.1111/j.1460-9568.2007.05470.x

ANM Schoffelmeer, 2006, Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core, Neuropharmacology, 51, 773, 10.1016/j.neuropharm.2006.05.019

D Viganò, 2004, Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine, European Journal of Neuroscience, 20, 1849, 10.1111/j.1460-9568.2004.03645.x

S Gonzalez, 2002, Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels, Drug and Alcohol Dependence, 66, 77, 10.1016/S0376-8716(01)00186-7

J Chu, 2010, Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization, Cellular Signalling, 22, 684, 10.1016/j.cellsig.2009.12.003

F Berrendero, 2003, Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice, Eur J Neurosci, 18, 2197, 10.1046/j.1460-9568.2003.02951.x

P Marini, 2009, Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: interactions with muscarinic and delta-opioid receptors, Biochimica Et Biophysica Acta-Molecular Cell Research, 1793, 1289, 10.1016/j.bbamcr.2009.05.002

MS Spano, 2004, CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat, British Journal of Pharmacology, 143, 343, 10.1038/sj.bjp.0705932

Z Justinova, 2008, Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB1-receptor antagonist rimonabant, Neuropsychopharmacology, 33, 2870, 10.1038/npp.2008.21

D Braida, 2004, Δ⁹-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats, European Journal of Pharmacology, 506, 63, 10.1016/j.ejphar.2004.10.043

M Solinas, 2004, beta-Endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol, European Journal of Neuroscience, 19, 3183, 10.1111/j.0953-816X.2004.03420.x

SP Welch, 1992, Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice, Journal of Pharmacology and Experimental Therapeutics, 262, 10

G Pugh, 1996, The role of endogenous opioids in enhancing the antinociception produced by the combination of delta-9-tetrahydrocannabinol and morphine in the spinal cord, Journal of Pharmacology and Experimental Therapeutics, 279, 608

DL Cichewicz, 1999, Enhancement of μ opioid antinociception by oral Δ⁹-tetrahydrocannabinol: dose-response analysis and receptor identification, Journal of Pharmacology and Experimental Therapeutics, 289, 859

ML Cox, 2007, Synergy between Δ⁹-tetrahydrocannabinol and morphine in the arthritic rat, European Journal of Pharmacology, 567, 125, 10.1016/j.ejphar.2007.04.010

I Reche, 1996, Potentiation of Δ⁹-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptors, European Journal of Pharmacology, 318, 11, 10.1016/S0014-2999(96)00752-2

WS Loewe, 1928, Die quantitative Problem der Pharmakologie, Ergebnisse der Physiologie, 27, 47, 10.1007/BF02322290

WS Loewe, 1940, Synergism of cannabis and butyl-bromathyl-barbituric acid, Journal of the American Pharmaceutical Association (Scientific edition), 29, 162, 10.1002/jps.3030290404

Loewe WS (1944) Studies on the pharmacology of marihuana. In: Committee L, editor. The Marihuana Problem in the City of New York. Lancaster, PA: Jaques Cattell Press. pp. 149–212.

WS Loewe, 1941, The action of chemical components of cannabis extracts, Journal of Pharmacology and Experimental Therapeutics, 72, 72

WS Loewe, 1945, Marihuana activity of cannabinol, Science, 102, 615, 10.1126/science.102.2659.615

JD Roberts, 2006, Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine, European Journal of Pharmacology, 530, 54, 10.1016/j.ejphar.2005.11.036

F Berrendero, 2002, Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol, Psychopharmacology, 163, 111, 10.1007/s00213-002-1144-9

I Reche, 1998, Inhibition of opioid-degrading enzymes potentiates Δ⁹-tetrahydrocannabinol-induced antinociception in mice, Neuropharmacology, 37, 215, 10.1016/S0028-3908(98)00005-7

M Haney, 2003, Interaction between naltrexone and oral THC in heavy marijuana smokers, Psychopharmacology, 166, 77, 10.1007/s00213-002-1279-8

ZD Cooper, 2010, Opioid antagonism enhances marijuana's effects in heavy marijuana smokers, Psychopharmacology (Berl), 211, 141, 10.1007/s00213-010-1875-y

DT Malone, 1998, Modulation of Δ⁹-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat, British Journal of Pharmacology, 124, 1419, 10.1038/sj.bjp.0701980

M Goddard, 2010, Behavioural effects of co-administration of delta 9-tetrahydrocannabinol with fluoxetine in rats, Pharmacology, 86, 125, 10.1159/000317059

MN Hill, 2008, Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents, Journal of Neural Transmission, 115, 1673, 10.1007/s00702-008-0131-7

A Rodriguez-Gaztelumendi, 2009, Altered CB1 receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine, Journal of Neurochemistry, 108, 1423, 10.1111/j.1471-4159.2009.05898.x

SA Hesketh, 2008, Effects of chronic treatment with citalopram on cannabinoid and opioid receptor-mediated G-protein coupling in discrete rat brain regions, Psychopharmacology, 198, 29, 10.1007/s00213-007-1033-3

W Wang, 2010, Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress, Neuropsychopharmacology, 35, 2249, 10.1038/npp.2010.99

S Mato, 2010, Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine_1A receptor-dependent mechanisms, Molecular Pharmacology, 77, 424, 10.1124/mol.109.060079

MN Hill, 2006, Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis, Neuropsychopharmacology, 31, 2591, 10.1038/sj.npp.1301092

MN Hill, 2008, Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment, Journal of Neurochemistry, 106, 2322, 10.1111/j.1471-4159.2008.05567.x

N Gobshtis, 2007, Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness, European Journal of Pharmacology, 554, 155, 10.1016/j.ejphar.2006.10.028

MN Hill, 2007, Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity, Journal of Neurochemistry, 103, 47, 10.1111/j.1471-4159.2007.04688.x

GA Gray, 1987, Enhancement of the hypothermic response of mice to delta-9-tetrahydrocannabinol by subhypothermic doses of chlorpromazine and phentolamine, Neuropharmacology, 23, 229, 10.1016/0028-3908(87)90213-9

M Andersson, 2005, Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia, J Neurosci Res, 82, 264, 10.1002/jnr.20630

S Sundram, 2005, Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens, Naunyn Schmiedebergs Arch Pharmacol, 371, 428, 10.1007/s00210-005-1074-2

DR Schulze, 2012, Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys, Psychopharmacology, 222, 425, 10.1007/s00213-012-2661-9

A Secher, 2010, Risperidone treatment increases CB1 receptor binding in rat brain, Neuroendocrinology, 91, 155, 10.1159/000245220

MC Cheng, 2008, Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex, International Journal of Neuropsychopharmacology, 11, 207, 10.1017/S1461145707008048

LCD Rodrigues, 2011, Clozapine and SCH 23390 prevent the spatial working memory disruption induced by Delta(9)-THC administration into the medial prefrontal cortex, Brain Research, 1382, 230, 10.1016/j.brainres.2011.01.069

DC D'Souza, 2008, Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans, Psychopharmacology, 198, 587, 10.1007/s00213-007-1042-2

M Liem-Moolenaar, 2010, Central nervous system effects of haloperidol on THC in healthy male volunteers, Journal of Psychopharmacology, 24, 1697, 10.1177/0269881109358200

D Kleinloog, 2012, Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol, Journal of Psychopharmacology, 26, 1307, 10.1177/0269881112446534

N Naderi, 2008, Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice, Pharmacol Biochem Behav, 89, 64, 10.1016/j.pbb.2007.11.001

V Micale, 2009, Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: possible involvement of the endocannabinoid and endovanilloid systems, Neurobiology of Disease, 36, 70, 10.1016/j.nbd.2009.06.015

MS Garcia-Gutierrez, 2010, The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines, Journal of Psychopharmacology, 24, 757, 10.1177/0269881109106910

L Urigüen, 2004, Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors, Neuropharmacology, 46, 966, 10.1016/j.neuropharm.2004.01.003

V Micale, 2009, Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels, Neuropsychopharmacology, 34, 593, 10.1038/npp.2008.98

RG Pertwee, 1988, Drugs that stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol-induced to produce marked catalepsy in mice, Neuropharmacology, 27, 1265, 10.1016/0028-3908(88)90029-9

A Sulkowski, 1977, Propranolol effects on acute marihuana intoxication in man, Psychopharmacology (Berl), 23, 47, 10.1007/BF00426599

F Weis, 2010, Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery, British Journal of Anaesthesia, 105, 139, 10.1093/bja/aeq117

GT Pryor, 1977, Interactions between delta9-tetrahydrocannabinol and phencyclidine hydrochloride in rats, Pharmacology Biochemistry and Behavior, 6, 123, 10.1016/0091-3057(77)90168-X

JM McPartland, 1997, Medical marijuana and its use by the immunocompromised, Altern Ther Health Med, 3, 39

GP Novelli, 1983, Analgesic interaction between nitrous oxide and delta-9-tetrahydrocannabinol in the rat, British Journal of Anaesthesia, 55, 997, 10.1093/bja/55.10.997

N Naderi, 2008, Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice, Journal of Neural Transmission, 115, 1501, 10.1007/s00702-008-0076-x

K Goffin, 2008, An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam, Neuropharmacology, 54, 1103, 10.1016/j.neuropharm.2008.02.018

RG Pertwee, 1991, An investigation of the involvement of GABA in certain pharmacological effects of delta-9-tetrahydrocannabinol, Pharmacology Biochemistry and Behavior, 40, 581, 10.1016/0091-3057(91)90366-A

JA Lile, 2012, Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ⁹-THC in humans discriminating Δ⁹-THC, Drug and Alcohol Dependence, 122, 61, 10.1016/j.drugalcdep.2011.09.010

JJ Luszczki, 2012, Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis, Pharmacological Reports, 64, 723, 10.1016/S1734-1140(12)70867-8

S Banni, 2012, Vagus nerve stimulation reduces body weight and fat mass in rats, Plos One, 7, 10.1371/journal.pone.0044813

G Burdyga, 2010, Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype, American Journal of Physiology-Gastrointestinal and Liver Physiology, 299, G63, 10.1152/ajpgi.00059.2010

ND Riediger, 2009, A systemic review of the roles of n-3 fatty acids in health and disease, Journal of the American Dietetic Association, 109, 668, 10.1016/j.jada.2008.12.022

AR Alvheim, 2012, Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity, Obesity, 20, 1984, 10.1038/oby.2012.38

HL Hutchins-Wiese, 2012, Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle, Journal of Nutritional Biochemistry, 23, 986, 10.1016/j.jnutbio.2011.05.005

JT Wood, 2010, Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma, Journal of Lipid Research, 51, 1416, 10.1194/jlr.M002436

F Piscitelli, 2011, Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice, Nutrition & Metabolism, 8, 10.1186/1743-7075-8-51

M Lafourcade, 2011, Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions, Nature Neuroscience, 14, 345, 10.1038/nn.2736

T Larrieu, 2012, Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice, Journal of Physiology and Biochemistry, 68, 671, 10.1007/s13105-012-0179-6

A Berger, 2001, Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets (vol 98, pg 6402, 2001), Proceedings of the National Academy of Sciences of the United States of America, 98, 7647, 10.1073/pnas.101119098

T Bisogno, 1999, Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina, Archives of Biochemistry and Biophysics, 370, 300, 10.1006/abbi.1999.1410

I Brown, 2010, Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines, Carcinogenesis, 31, 1584, 10.1093/carcin/bgq151

HY Kim, 2013, Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function, Prostaglandins Leukotrienes and Essential Fatty Acids, 88, 121, 10.1016/j.plefa.2012.08.002

JP Schuchardt, 2011, Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations–a comparative bioavailability study of fish oil vs. krill oil, Lipids Health Dis, 10, 145, 10.1186/1476-511X-10-145

B Batetta, 2009, Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats, Journal of Nutrition, 139, 1495, 10.3945/jn.109.104844

V Di Marzo, 2010, Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats, International Dairy Journal, 20, 231, 10.1016/j.idairyj.2009.11.015

S Banni, 2011, Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects, Nutr Metab (Lond), 8, 7, 10.1186/1743-7075-8-7

C Rousseaux, 2007, Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 13, 35, 10.1038/nm1521

FA Palermo, 2011, Modulation of cortisol levels, endocannabinoid receptor 1A, proopiomelanocortin and thyroid hormone receptor alpha mRNA expressions by probiotics during sole (Solea solea) larval development, General and Comparative Endocrinology, 171, 293, 10.1016/j.ygcen.2011.02.009

GG Muccioli, 2010, The endocannabinoid system links gut microbiota to adipogenesis, Molecular Systems Biology, 6, 10.1038/msb.2010.46

N Crouzin, 2011, alpha-tocopherol and alpha-tocopheryl phosphate interact with the cannabinoid system in the rodent hippocampus, Free Radic Biol Med, 51, 1643, 10.1016/j.freeradbiomed.2011.07.012

V Di Marzo, 1998, Trick or treat from food endocannabinoids, Nature, 396, 636, 10.1038/25267

G Crozier Willi, 2001, Lipids in neural function: modulation of behavior by oral administration of endocannabinoids found in foods, Nestle Nutr Workshop Ser Clin Perform Programme, 169, 10.1159/000061850

E Fride, 2001, Critical role of the endogenous cannabinoid system in mouse pup suckling and growth, Eur J Pharmacol, 419, 207, 10.1016/S0014-2999(01)00953-0

RL Carr, 2011, Effect of developmental chlorpyrifos exposure, on endocannabinoid metabolizing enzymes, in the brain of juvenile rats, Toxicological Sciences, 122, 112, 10.1093/toxsci/kfr081

CB Quistad, 2001, Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides, Toxicology and Applied Pharmacology, 173, 48, 10.1006/taap.2001.9175

AS Dhopeshwarkar, 2011, The actions of benzophenanthridine alkaloids, piperonyl butoxide and (S)-methoprene at the G-protein coupled cannabinoid CB1 receptor in vitro, European Journal of Pharmacology, 654, 26, 10.1016/j.ejphar.2010.11.033

KM Bisset, 2011, The G protein-coupled cannabinoid-1 (CB₁) receptor of mammalian brain: inhibition by phthalate esters in vitro, Neurochemistry International, 59, 706, 10.1016/j.neuint.2011.06.019

KAB Simao da Silva, 2011, Activation of cannabinoid receptors by the pentacyclic triterpene alpha,beta-amyrin inhibits inflammatory and neuropathic persistent pain in mice, Pain, 152, 1872, 10.1016/j.pain.2011.04.005

JP Meschler, 1999, Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses, Pharmacology Biochemistry and Behavior, 62, 473, 10.1016/S0091-3057(98)00195-6

AR King, 2009, Discovery of potent and reversible monoacylglycerol lipase inhibitors, Chem Biol, 16, 1045, 10.1016/j.chembiol.2009.09.012

R Capasso, 2008, Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB1 receptors, British Journal of Pharmacology, 155, 681, 10.1038/bjp.2008.294

J Fichna, 2012, Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors, Inflammatory Bowel Diseases, 18, 1137, 10.1002/ibd.21873

L Thors, 2010, Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase, British Journal of Pharmacology, 160, 549, 10.1111/j.1476-5381.2010.00716.x

G Korte, 2009, An examination of anthocyanins' and anthocyanidins' affinity for cannabinoid receptors, Journal of Medicinal Food, 12, 1407, 10.1089/jmf.2008.0243

G Korte, 2010, Tea catechins' affinity for human cannabinoid receptors, Phytomedicine, 17, 19, 10.1016/j.phymed.2009.10.001

A Ligresti, 2012, Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB1 receptor ligand, Pharmacological Research, 66, 163, 10.1016/j.phrs.2012.04.003

P Hassanzadeh, 2012, The CB1 receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin, Neurochemical Research, 37, 1112, 10.1007/s11064-012-0716-2

PL Prather, 2009, The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists (vol 330, pg 31, 2009), Journal of Pharmacology and Experimental Therapeutics, 331, 1147

B Botta, 2003, Three isoflavanones with cannabinoid-like moieties from Desmodium canum, Phytochemistry, 64, 599, 10.1016/S0031-9422(03)00201-2

I Muhammad, 2001, Antimalarial (+)-trans-hexahydrodibenzopyran derivatives from Machaerium multiflorum, Journal of Natural Products, 64, 1322, 10.1021/np0102861

F Bohlmann, 1979, Cannabigerol-ähnliche verbendungen aus <italic>Helichrysum umbraculigerum</italic>, Phytochemistry, 18, 1371, 10.1016/0031-9422(79)83025-3

N Iwata, 2011, New cannabinoid-like chromane and chromene derivatives from Rhododendron anthopogonoides, Chemical & Pharmaceutical Bulletin, 59, 1409, 10.1248/cpb.59.1409

L Harinantenaina, 2006, Chemical constituents of malagasy liverworts, Part V: Prenyl bibenzyls and clerodane diterpenoids with nitric oxide inhibitory activity from Radula appressa and Thysananthus spathulistipus, Chemical & Pharmaceutical Bulletin, 54, 1046, 10.1248/cpb.54.1046

M Toyota, 2002, New bibenzyl cannabinoid from the New Zealand liverwort Radula marginata, Chemical & Pharmaceutical Bulletin, 50, 1390, 10.1248/cpb.50.1390

JT Gao, 2011, Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens, Journal of Natural Products, 74, 1636, 10.1021/np200147c

H Lin, 2001, Two novel phenylacetoxylated p-terphenyls from Thelephora ganbajun Zang, Z Naturforsch C, 56, 983, 10.1515/znc-2001-11-1213

K Quaghebeur, 1994, Cannabiorci- and 8-chlorocannabiorcichromenic acid as fungal antagonists from Cylindrocarpon olidum, Phytochemistry, 37, 159, 10.1016/0031-9422(94)85016-X

M Leonti, 2010, Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin, Biochemical Pharmacology, 79, 1815, 10.1016/j.bcp.2010.02.015

TK Zank, 2000, Cloning and functional expression of the first plant fatty acid elongase specific for Delta(6)-polyunsaturated fatty acids, Biochemical Society Transactions, 28, 654, 10.1042/bst0280654

E di Tomaso, 1996, Brain cannabinoids in chocolate, Nature, 382, 677, 10.1038/382677a0

S Nakane, 2000, Occurrence of a novel cannabimimetic molecule 2- sciadonoylglycerol (2-eicosa-5′, 11′, 14′-trienoylglycerol) in the umbrella pine Sciadopitys verticillata seeds, Biological & Pharmaceutical Bulletin, 23, 758, 10.1248/bpb.23.758

M Gutierrez, 2011, Cannabinomimetic lipid from a marine cyanobacterium, Journal of Natural Products, 74, 2313, 10.1021/np200610t

N Sitachitta, 1998, Grenadadiene and grenadamide, cyclopropyl-containing fatty acid metabolites from the marine cyanobacterium Lyngbya majuscula, J Nat Prod, 61, 681, 10.1021/np970576a

K Soderstrom, 1997, Discovery of novel cannabinoid receptor ligands from diverse marine organisms, Advances in Experimental Medicine and Biology, 433, 73, 10.1007/978-1-4899-1810-9_14

S Raduner, 2006, Alkylamides from Echinacea are a new class of cannabinomimetics - cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects, Journal of Biological Chemistry, 281, 14192, 10.1074/jbc.M601074200

A Chicca, 2009, Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts, International Immunopharmacology, 9, 850, 10.1016/j.intimp.2009.03.006

J Hohmann, 2011, Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors, Phytochemistry, 72, 1848, 10.1016/j.phytochem.2011.06.008

J Gertsch, 2008, Beta-caryophyllene is a dietary cannabinoid, Proceedings of the National Academy of Sciences of the United States of America, 105, 9099, 10.1073/pnas.0803601105

AF Bento, 2011, Beta-caryophyllene inhibits dextran sulfate sodium-Induced colitis in mice through CB2 receptor activation and PPAR gamma pathway, American Journal of Pathology, 178, 1153, 10.1016/j.ajpath.2010.11.052

B Horvath, 2012, β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner, Free Radical Biology and Medicine, 52, 1325, 10.1016/j.freeradbiomed.2012.01.014

S Katsuyama, 2013, Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception, European Journal of Pain, 17, 664, 10.1002/j.1532-2149.2012.00242.x

JM Rollinger, 2009, In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens, Planta Med, 75, 195, 10.1055/s-0028-1088397

AK Palu, 2008, The effects of Morinda citrifolia L. (noni) on the immune system: its molecular mechanisms of action, Journal of Ethnopharmacology, 115, 502, 10.1016/j.jep.2007.10.023

M Quartu, 2012, Effect of acute administration of Pistacia lentiscus L. essential oil on rat cerebral cortex following transient bilateral common carotid artery occlusion, Lipids in Health and Disease, 11, 10.1186/1476-511X-11-8

N Sepe, 1998, Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs - Possible implications for mollusc physiology and seafood industry, Biochimica et Biophysica Acta Lipids and Lipid Metabolism, 1389, 101, 10.1016/S0005-2760(97)00132-X

T Bisogno, 1997, Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus, Biochimica et Biophysica Acta Lipids and Lipid Metabolism, 1345, 338, 10.1016/S0005-2760(97)00009-X

I Matias, 2005, Occurrence and possible biological role of the endocannabinoid system in the sea squirt Ciona intestinalis, Journal of Neurochemistry, 93, 1141, 10.1111/j.1471-4159.2005.03103.x

MN Hill, 2010, Endogenous cannabinoid signaling is essential for stress adaptation, Proceedings of the National Academy of Sciences of the United States of America, 107, 9406, 10.1073/pnas.0914661107

S Patel, 2005, Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling, European Journal of Neuroscience, 21, 1057, 10.1111/j.1460-9568.2005.03916.x

MN Hill, 2005, Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress, Neuropsychopharmacology, 30, 508, 10.1038/sj.npp.1300601

S Patel, 2009, Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at iInhibitory synapses in basolateral amygdala, Neuropsychopharmacology, 34, 2699, 10.1038/npp.2009.101

NK Evanson, 2010, Fast feedback inhibition of the HPA axis by glucocorticoids Is mediated by endocannabinoid signaling, Endocrinology, 151, 4811, 10.1210/en.2010-0285

CG Reich, 2009, Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats, Behavioural Brain Research, 203, 264, 10.1016/j.bbr.2009.05.013

NR Sciolino, 2010, Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats, Neuroscience, 168, 371, 10.1016/j.neuroscience.2010.04.007

S Zoppi, 2011, Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation, Neuropsychopharmacology, 36, 805, 10.1038/npp.2010.214

M Bortolato, 2007, Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress, Biological Psychiatry, 62, 1103, 10.1016/j.biopsych.2006.12.001

TTY Lee, 2013, Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB1 receptor binding in male rats, Neuroscience, 249, 106, 10.1016/j.neuroscience.2012.11.017

SS Hong, 2011, Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat, Gastroenterology, 140, 627, 10.1053/j.gastro.2010.11.003

S Dubreucq, 2012, Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice, Neuropsychopharmacology, 37, 1885, 10.1038/npp.2012.36

S Rossi, 2008, Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum, Journal of Neuroscience, 28, 7284, 10.1523/JNEUROSCI.5346-07.2008

W Hu, 2011, Chronic restraint stress impairs endocannabinoid mediated suppression of GABAergic signaling in the hippocampus of adult male rats, Brain Research Bulletin, 85, 374, 10.1016/j.brainresbull.2011.04.005

JI Wamsteeker, 2010, Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus, Journal of Neuroscience, 30, 11188, 10.1523/JNEUROSCI.1046-10.2010

AG Hohmann, 2005, An endocannabinoid mechanism for stress-induced analgesia, Nature, 435, 1108, 10.1038/nature03658

K Connell, 2006, Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia, Neuroscience Letters, 397, 180, 10.1016/j.neulet.2005.12.008

P Campolongo, 2009, Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory, Proceedings of the National Academy of Sciences of the United States of America, 106, 4888, 10.1073/pnas.0900835106

E Coddington, 2007, Endocannabinoids mediate the effects of acute stress and corticosterone on sex behavior, Endocrinology, 148, 493, 10.1210/en.2006-0740

MN Wang, 2012, Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation, Journal of Psychopharmacology, 26, 56, 10.1177/0269881111409606

HB Bradshaw, 2006, Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators, American Journal of Physiology-Regulatory Integrative and Comparative Physiology, 291, R349, 10.1152/ajpregu.00933.2005

AJ Dunnett, 2007, The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase, Journal of Bodywork and Movement Therapies, 11, 99, 10.1016/j.jbmt.2006.12.004

JM McPartland, 2005, Cannabimimetic effects of osteopathic manipulative treatment, Journal of the American Osteopathic Association, 105, 283

V Trezza, 2012, Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats, Journal of Neuroscience, 32, 14899, 10.1523/JNEUROSCI.0114-12.2012

M Navarro, 1997, Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat, Neuroreport, 8, 491, 10.1097/00001756-199701200-00023

HJ Park, 2011, Effect of acupuncture on hypothalamic-pituitary-adrenal system in maternal separation rats, Cell Mol Neurobiol, 31, 1123, 10.1007/s10571-011-9718-x

L Chen, 2009, Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats, Journal of Pain, 10, 732, 10.1016/j.jpain.2008.12.012

J Zhang, 2010, Electroacupuncture increases CB2 receptor expression on keratinocytes and infiltrating inflammatory cells in inflamed skin tissues of rats, Journal of Pain, 11, 1250, 10.1016/j.jpain.2010.02.013

TF Su, 2011, Cannabinoid CB2 receptors contribute to upregulation of beta-endorphin in inflamed skin tissues by electroacupuncture, Molecular Pain, 7

LW Fu, 2009, Electroacupuncture modulates vlPAG release of GABA through presynaptic cannabinoid CB1 receptors, J Appl Physiol, 106, 1800, 10.1152/japplphysiol.91648.2008

QA Wang, 2011, Activation of epsilon protein kinase C-mediated anti-apoptosis is involved in rapid tolerance induced by electroacupuncture pretreatment through cannabinoid receptor type 1, Stroke, 42, 389, 10.1161/STROKEAHA.110.597336

NA Darmani, 2005, Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies, Neuropharmacology, 48, 1154, 10.1016/j.neuropharm.2005.01.001

V Di Marzo, 2011, Endocannabinoids: an appetite for fat, Proc Natl Acad Sci U S A, 108, 12567, 10.1073/pnas.1109567108

V Di Marzo, 2005, Endocannabinoid control of food intake and energy balance, Nature Neuroscience, 8, 585, 10.1038/nn1457

M Cote, 2007, Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men, International Journal of Obesity, 31, 692, 10.1038/sj.ijo.0803539

F Massa, 2010, Alterations in the hippocampal endocannabinoid system in diet-Induced obese mice, Journal of Neuroscience, 30, 6273, 10.1523/JNEUROSCI.2648-09.2010

S Engeli, 2005, Activation of the peripheral endocannabinoid system in human obesity, Diabetes, 54, 2838, 10.2337/diabetes.54.10.2838

MF Bennetzen, 2011, Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss, International Journal of Obesity, 35, 1377, 10.1038/ijo.2011.8

V Di Marzo, 2009, Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors, Diabetologia, 52, 213, 10.1007/s00125-008-1178-6

TJ You, 2011, Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise, Lipids in Health and Disease, 10

I Matias, 2012, Endocannabinoids measurement in human saliva as potential biomarker of obesity, Plos One, 7, 10.1371/journal.pone.0042399

PB Sparling, 2003, Exercise activates the endocannabinoid system, Neuroreport, 14, 2209, 10.1097/00001756-200312020-00015

E Heyman, 2012, Intense exercise increases circulating endocannabinoid and BDNF levels in humans - possible implications for reward and depression, Psychoneuroendocrinology, 37, 844, 10.1016/j.psyneuen.2011.09.017

M Feuerecker, 2012, Effects of exercise stress on the endocannabinoid system in humans under field conditions, European Journal of Applied Physiology, 112, 2777, 10.1007/s00421-011-2237-0

DA Raichlen, 2012, Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the ‘runner&apos;s high’, Journal of Experimental Biology, 215, 1331, 10.1242/jeb.063677

DA Raichlen, 2013, Exercise-induced endocannabinoid signaling is modulated by intensity, European Journal of Applied Physiology, 113, 869, 10.1007/s00421-012-2495-5

B Ferrer, 2007, Regulation of brain anandamide by acute administration of ethanol, Biochemical Journal, 404, 97, 10.1042/BJ20061898

BS Basavarajappa, 2008, Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons, Journal of Neurochemistry, 107, 1001, 10.1111/j.1471-4159.2008.05685.x

S Perra, 2005, Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo, Psychopharmacology, 183, 368, 10.1007/s00213-005-0195-0

S Perra, 2008, Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system, Alcoholism-Clinical and Experimental Research, 32, 443, 10.1111/j.1530-0277.2007.00588.x

HH Yin, 2007, Ethanol reverses the direction of long-term synaptic plasticity in the dorsomedial striatum, Eur J Neurosci, 25, 3226, 10.1111/j.1460-9568.2007.05606.x

RBC Clarke, 2010, Acute ethanol treatment prevents endocannabinoid-mediated long-lasting disinhibition of striatal output, Neuropharmacology, 58, 799, 10.1016/j.neuropharm.2009.12.006

BS Basavarajappa, 1998, Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane, Brain Res, 793, 212, 10.1016/S0006-8993(98)00175-9

BS Basavarajappa, 1999, Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse, Brain Res, 815, 89, 10.1016/S0006-8993(98)01072-5

S Ortiz, 2004, Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain, Alcohol Alcohol, 39, 88, 10.1093/alcalc/agh036

KY Vinod, 2012, Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats, Addiction Biology, 17, 62, 10.1111/j.1369-1600.2010.00299.x

KY Vinod, 2006, Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system, Neurochemistry International, 49, 619, 10.1016/j.neuint.2006.05.002

R Rimondini, 2002, Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol, Faseb Journal, 16, 27, 10.1096/fj.01-0593com

S Mitrirattanakul, 2007, Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence, Alcohol Clin Exp Res, 31, 855, 10.1111/j.1530-0277.2007.00366.x

L Adermark, 2011, Intermittent ethanol consumption depresses endocannabinoid-signaling in the dorsolateral striatum of rat, Neuropharmacology, 61, 1160, 10.1016/j.neuropharm.2011.01.014

M Feuerecker, 2012, Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans, Alcohol and Alcoholism, 47, 226, 10.1093/alcalc/agr162

KY Vinod, 2010, Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides, Journal of Psychiatric Research, 44, 591, 10.1016/j.jpsychires.2009.11.013

S Gonzalez, 2002, Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine, Brain Research, 954, 73, 10.1016/S0006-8993(02)03344-9

DM Penetar, 2005, Transdermal nicotine alters some of marihuana&apos;s effects in male and female volunteers, Drug Alcohol Depend, 79, 211, 10.1016/j.drugalcdep.2005.01.008

GN Balerio, 2006, Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice, Psychopharmacology (Berl), 184, 504, 10.1007/s00213-005-0251-9

B Le Foll, 2006, Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats, Behav Pharmacol, 17, 195, 10.1097/01.fbp.0000197460.16516.81

GT Pryor, 1978, Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats, Pharmacol Biochem Behav, 8, 295, 10.1016/0091-3057(78)90320-9

M Solinas, 2007, Nicotinic facilitation of delta-9-tetrahydrocannabinol discrimination involves endogenous anandamide, Journal of Pharmacology and Experimental Therapeutics, 321, 1127, 10.1124/jpet.106.116830

E Valjent, 2002, Behavioural and biochemical evidence for interactions between Δ⁹-tetrahydrocannabinol and nicotine, British Journal of Pharmacology, 135, 564, 10.1038/sj.bjp.0704479

MR Jafari, 2007, Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice, Behav Pharmacol, 18, 691, 10.1097/FBP.0b013e3282f00c10

A Cippitelli, 2011, Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect ofFAAH inhibition, PLoS ONE, 6, 10.1371/journal.pone.0028142

AD Smith, 2006, Mouse cerebellar nicotinic-cholinergic receptor modulation of Δ⁹-THC ataxia: role of the α₄β₂ subtype, Brain Research, 1115, 16, 10.1016/j.brainres.2006.07.075

MW Buczynski, 2013, The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area, Neuropsychopharmacology, 38, 574, 10.1038/npp.2012.210

EM Marco, 2006, Adolescent exposure to nicotine modifies acute functional responses to cannabinoid agonists in rats, Behav Brain Res, 172, 46, 10.1016/j.bbr.2006.04.012

LL Werling, 2009, Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats, International Journal of Developmental Neuroscience, 27, 263, 10.1016/j.ijdevneu.2008.12.008

L Robinson, 2010, WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction, Behavioural Brain Research, 208, 584, 10.1016/j.bbr.2010.01.004

J Bell, 1857, On the haschisch or Cannabis indica, Boston Medical and Surgical Journal, 56, 209, 10.1056/NEJM185704160561101

AF Hoffman, 2010, Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A₁ receptors, Journal of Neuroscience, 30, 545, 10.1523/JNEUROSCI.4920-09.2010

DE Selley, 2004, Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum, Mol Pharmacol, 66, 1275, 10.1124/mol.104.000604

JM McPartland, 1997, Caffeine and chronic back pain, Archives of Physical Medicine and Rehabilitation, 78, 61, 10.1016/S0003-9993(97)90011-3

P Consroe, 1976, EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits, Psychopharmacology (Berl), 50, 47, 10.1007/BF00634153

S Rossi, 2009, Caffeine drinking potentiates cannabinoid transmission in the striatum: Interaction with stress effects, Neuropharmacology, 56, 590, 10.1016/j.neuropharm.2008.10.013

VC Sousa, 2011, Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A₁ receptors and chronic caffeine administration: Implications for the effects of Δ⁹-tetrahydrocannabinol on spatial memory, Neuropsychopharmacology, 36, 472, 10.1038/npp.2010.179

R Mechoulam, 1998, Endocannabinoids, Eur J Pharmacol, 359, 1, 10.1016/S0014-2999(98)00649-9

McPartland JM, Guy GW (2004) The evolution of Cannabis and coevolution with the cannabinoid receptor—a hypothesis. In: Guy GW, Robson R, Strong K, Whittle B, editors. The Medicinal Use of Cannabis. London: Royal Society of Pharmacists. pp. 71–102.

DL Cichewicz, 2001, Opioid and cannabinoid receptor protein levels following chronic treatment, FASEB Journal, 15, A228

J Romero, 1995, Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta-9-tetrahydrocannabinol, Pharmacology Biochemistry and Behavior, 51, 731, 10.1016/0091-3057(95)00023-P

S Zhuang, 1998, Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions, Brain Res Mol Brain Res, 62, 141, 10.1016/S0169-328X(98)00232-0

LJ Sim, 1996, Effects of chronic treatment with Δ⁹-tetrahydrocannabinol on cannabinoid-stimulated [³⁵S]GTPγS autoradiography in rat brain, Journal of Neuroscience, 16, 8057, 10.1523/JNEUROSCI.16-24-08057.1996

SH Burstein, 1995, Stimulation of anandamide biosynthesis in N-18TG2 neuroblastoma cells by delta-9-tetrahydrocannabinol (THC), Biochemical Pharmacology, 49, p855, 10.1016/0006-2952(94)00538-W

CS Breivogel, 1999, Chronic Δ⁹-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain, Journal of Neurochemistry, 73, 2447, 10.1046/j.1471-4159.1999.0732447.x

KW Falenski, 2010, FAAH^−/− mice display differential tolerance, dependence, and cannabinoid receptor adaptation after Δ⁹-tetrahydrocannabinol and anandamide administration, Neuropsychopharmacology, 35, 1775, 10.1038/npp.2010.44

V Di Marzo, 2000, Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of D⁹-tetrahydrocannabinol-tolerant rats, Journal of Neurochemistry, 74, 1627, 10.1046/j.1471-4159.2000.0741627.x

J Villares, 2007, Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain, Neuroscience, 145, 323, 10.1016/j.neuroscience.2006.11.012

J Hirvonen, 2012, Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers, Molecular Psychiatry, 17, 642, 10.1038/mp.2011.82

DC D'Souza, 2008, Blunted Psychotomimetic and Amnestic Effects of Delta-9-Tetrahydrocannabinol in Frequent Users of Cannabis, Neuropsychopharmacology

A Rotter, 2013, CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence, European Addiction Research, 19, 13, 10.1159/000338642

DJ Lundberg, 2005, Δ⁹-Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture, Neuropharmacology, 49, 1170, 10.1016/j.neuropharm.2005.07.012

C Hsieh, 1999, Internalization and recycling of the CB1 cannabinoid receptor, J Neurochem, 73, 493, 10.1046/j.1471-4159.1999.0730493.x

F Fan, 1994, Development of cross-tolerance between delta-9-tetrahydrocannabinol, CP 55,940 and WIN 55,212, Journal of Pharmacology and Experimental Therapeutics, 271, 1383

T Luk, 2004, Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist, British Journal of Pharmacology, 142, 495, 10.1038/sj.bjp.0705792

LJ Sim-Selley, 2002, Effect of chronic administration of <italic>R</italic>-(+)-[2,3-dihydro-5- methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-<italic>de</italic>]-1,4- benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or Δ⁹-tetrahydrocannabinol on cannabinoid receptor adaptation in mice, Journal of Pharmacology and Experimental Therapeutics, 303, 36, 10.1124/jpet.102.035618

N Laaris, 2010, Δ⁹-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus, Neuropharmacology, 59, 121, 10.1016/j.neuropharm.2010.04.013

M Shen, 1999, Δ⁹-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture, Molecular Pharmacology, 55, 8, 10.1124/mol.55.1.8

A Straiker, 2005, Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones, Journal of Physiology-London, 569, 501, 10.1113/jphysiol.2005.091918

W Gonsiorek, 2000, Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide, Molecular Pharmacology, 57, 1045

JR Savinainen, 2001, Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB₁ receptor-dependent G-protein activation in rat cerebellar membranes, British Journal of Pharmacology, 134, 664, 10.1038/sj.bjp.0704297

N Stella, 1997, A second endogenous cannabinoid that modulates long-term potentiation, Nature, 388, 773, 10.1038/42015

NA Darmani, 2002, The potent emetogenic effects of the endocannabinoid, 2-AG (2- arachidonoylglycerol) are blocked by Δ⁹-tetrahydrocannabinol and other cannnabinoids, Journal of Pharmacology and Experimental Therapeutics, 300, 34, 10.1124/jpet.300.1.34

S Mato, 2004, A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity, Nat Neurosci, 7, 585, 10.1038/nn1251

BG Kelley, 2004, Δ⁹-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture, Neuropharmacology, 46, 709, 10.1016/j.neuropharm.2003.11.005

AM Roloff, 2009, Modulation of excitatory synaptic transmission by Δ⁹-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate, Molecular Pharmacology, 75, 892, 10.1124/mol.108.051482

TH Burkey, 1997, Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain, Eur J Pharmacol, 336, 295, 10.1016/S0014-2999(97)01255-7

MD Aceto, 1998, Anandamide, an endogenous cannabinoid, has a very low physical dependence potential, Journal of Pharmacology and Experimental Therapeutics, 287, 598

E Fride, 1995, Anandamides: tolerance and cross-tolerance to delta-9-tetrahydrocannabinol, Brain Research, 697, 83, 10.1016/0006-8993(95)00790-W

DW Bonhaus, 1998, Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses, J Pharmacol Exp Ther, 287, 884

M Glass, 1999, Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors, Mol Pharmacol, 56, 1362, 10.1124/mol.56.6.1362

E Fride, 1995, Low doses of anandamides inhibit pharmacological effects of delta-9-tetrahydrocannabinol, Journal of Pharmacology and Experimental Therapeutics, 272, 699

RG Pertwee, 1993, Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide, British Journal of Pharmacology, 110, 1483, 10.1111/j.1476-5381.1993.tb13989.x

RE Vann, 2012, Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride, Neuropharmacology, 62, 1019, 10.1016/j.neuropharm.2011.10.011

RL Suplita, 2008, Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia, Neuropharmacology, 54, 161, 10.1016/j.neuropharm.2007.07.006

JZ Long, 2009, Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo, Proceedings of the National Academy of Sciences of the United States of America, 106, 20270, 10.1073/pnas.0909411106

JM McPartland, 1999, Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana, Alternative Therapies in Health and Medicine, 5, 57

JM McPartland, 2001, Cannabis and cannabis extracts: Greater than the sum of their parts, Journal of Cannabis Therapeutics, 1, 103, 10.1300/J175v01n03_08

K Hayakawa, 2008, Cannabidiol potentiates pharmacological effects of Δ⁹-tetrahydrocannabinol via CB1 receptor-dependent mechanism, Brain Research, 1188, 157, 10.1016/j.brainres.2007.09.090

SA Wolf, 2010, Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis, Cell Communication and Signaling, 8

T Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, British Journal of Pharmacology, 134, 845, 10.1038/sj.bjp.0704327

L De Petrocellis, 2011, Effects of cannabinoids and cannabinoid-enriched <italic>Cannabis</italic> extracts on TRP channels and endocannabinoid metabolic enzymes, British Journal of Pharmacology, 163, 1479, 10.1111/j.1476-5381.2010.01166.x

JE Schlosburg, 2010, Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system, Nature Neuroscience, 13, 1113, 10.1038/nn.2616

S Watanabe, 2003, n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice, Prostaglandins Leukot Essent Fatty Acids, 69, 51, 10.1016/S0952-3278(03)00056-5

I Matias, 2008, Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes, Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids, 1781, 52, 10.1016/j.bbalip.2007.11.001

A Artmann, 2008, Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine, Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids, 1781, 200, 10.1016/j.bbalip.2008.01.006

TC Kirkham, 2002, Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol, British Journal of Pharmacology, 136, 550, 10.1038/sj.bjp.0704767

L Hanus, 2003, Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain, Brain Research, 983, 144, 10.1016/S0006-8993(03)03046-4

E Cottone, 2009, Goldfish CB1 mRNA expression is affected by fasting and anandamide administration, Neuroreport, 20, 595, 10.1097/WNR.0b013e32832a0a5f

M Valenti, 2005, The endocannabinoid system in the brain of Carassius auratus and its possible role in the control of food intake, Journal of Neurochemistry, 95, 662, 10.1111/j.1471-4159.2005.03406.x

A Guijarro, 2008, Sustained weight loss after roux-en-y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function, Annals of Surgery, 247, 779, 10.1097/SLA.0b013e318166fd5f

J Jelsing, 2009, The effect of leptin receptor deficiency and fasting on cannabinoid receptor 1 mRNA expression in the rat hypothalamus, brainstem and nodose ganglion, Neuroscience Letters, 463, 125, 10.1016/j.neulet.2009.07.011

ZC Yan, 2007, Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta, Biochemical and Biophysical Research Communications, 354, 427, 10.1016/j.bbrc.2006.12.213

S Rossi, 2009, Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis, Neurobiology of Disease, 36, 51, 10.1016/j.nbd.2009.06.013

V De Chiara, 2010, Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum, Neuropsychopharmacology, 35, 374, 10.1038/npp.2009.141

SG da Silva, 2010, Physical exercise in adolescence changes CB1 cannabinoid receptor expression in the rat brain, Neurochemistry International, 57, 492, 10.1016/j.neuint.2010.07.001

MN Hill, 2010, Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus, Hippocampus, 20, 513, 10.1002/hipo.20647

S Yasari, 2012, Effects of exercise training on molecular markers of lipogenesis and lipid partitioning in fructose-induced liver fat accumulation, J Nutr Metab, 2012, 181687, 10.1155/2012/181687

BS Basavarajappa, 1999, Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells, Journal of Neurochemistry, 72, 522, 10.1046/j.1471-4159.1999.0720522.x

BS Basavarajappa, 2000, Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons, Biochimica Et Biophysica Acta-Molecular Basis of Disease, 1535, 78, 10.1016/S0925-4439(00)00085-5

BS Basavarajappa, 2003, Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons, European Journal of Pharmacology, 466, 73, 10.1016/S0014-2999(03)01557-7

TH Burkey, 1997, delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain, Eur J Pharmacol, 323, R3, 10.1016/S0014-2999(97)00146-5

F Petitet, 1998, Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ⁹-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors, Life Sciences, 63, PL1, 10.1016/S0024-3205(98)00238-0